FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sean Emery

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sonja M Bjerk; Sean Emery; Fred M Gordin; Ken M Kunisaki; Jacqueline Neuhaus; Sarah L Pett; Christoph Stephan; Brian Angus; Jason V Baker
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.
Karen Schneider; David P Wilson; Jonathan Anderson; David A Cooper; Sean Emery; Richard Kaplan; Chidi A Nwizu; Mark A Boyd
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
Damien V Cordery; Sean Emery; Anthony D Kelleher; Allison Martin; Janaki Amin; David A Cooper
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sean Emery (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sonja M Bjerk; Sean Emery; Fred M Gordin; Ken M Kunisaki; Jacqueline Neuhaus; Sarah L Pett; Christoph Stephan; Brian Angus; Jason V Baker
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.
PloS one 2013;8(2):e56249.
2013: Karen Schneider; David P Wilson; Jonathan Anderson; David A Cooper; Sean Emery; Richard Kaplan; Chidi A Nwizu; Mark A Boyd
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
PloS one 2013;8(2):e54435.
2012: Damien V Cordery; Sean Emery; Anthony D Kelleher; Allison Martin; Janaki Amin; David A Cooper
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
AIDS (London, England) 2012;26(18):2337-44.
2012: Amit C Achhra; Janaki Amin; Haitao Chu; David A Cooper; David Dunn; Sean Emery; Joseph A Kovacs; Lewis H Kuller; Matthew G Law; Caroline Sabin
Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.
AIDS (London, England) 2012;26(13):1707-17.
2012: Dianne Carey; Kate Beileiter; Mark Bloch; Mark A Boyd; Sean Emery; Karen MacRae; Sarah L Pett; John E Ray; Handan Wand; David A Cooper
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Journal of acquired immune deficiency syndromes (1999) 2012;60(2):143-9.
2012: John M Murray; Kazuo Suzuki; John J Zaunders; Janaki Amin; Michelle Bailey; David Baker; Christoph Boesecke; David A Cooper; Sean Emery; Anthony D Kelleher; Kersten K Koelsch; Kristin McBride
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
AIDS (London, England) 2012;26(5):543-50.
2012: Hila Haskelberg; Jennifer F Hoy; Janaki Amin; Andrew Carr; Peter R Ebeling; Sean Emery
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
PloS one 2012;7(6):e38377.
2011: Helen Byakwaga; David A Cooper; Sean Emery; Martyn A French; Roger Garsia; Hila Haskelberg; Anthony D Kelleher; Mark Kelly; Sharon R Lewin; Damian F J Purcell; Janaki Amin; Mark A Boyd
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
The Journal of infectious diseases 2011;204(10):1532-40.
2011: Kersten K Koelsch; Kristin McBride; John M Murray; Ven Natarajan; John J Zaunders; David Baker; Mark Bloch; Christoph Boesecke; David A Cooper; Sean Emery; Paul Fahey; Linda Gelgor; Anthony D Kelleher
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir.
AIDS (London, England) 2011;25(17):2069-78.
2011: Hila Haskelberg; Andrew Carr; Sean Emery
Bone turnover markers in HIV disease.
AIDS reviews 2011;13(4):240-50.
2011: Gail V Matthews; Julie Metcalf; Susan Orsega; Nicholaas Pool; Phumele Sangweni; Sean Emery; Zonghui Hu; Paul Khabo; Patrick Maja; Prince Manzini; Gugu Matchaba
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.
AIDS (London, England) 2011;25(14):1727-35.
2011: S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; David A Cooper; Sean Emery
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
HIV medicine 2011;12(4):219-27.
2011: Allison Martin; Janaki Amin; David Baker; Mark Bloch; Andrew Carr; David A Cooper; Sean Emery
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
PloS one 2011;6(10):e26885.
2010: Allison Martin; Janaki Amin; David A Cooper; Andrew Carr; Anthony D Kelleher; Mark Bloch; David Baker; Ian Woolley; Sean Emery
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.
AIDS (London, England) 2010;24(17):2657-63.
2010: Rebekah L Puls; Preeyaporn Srasuebkul; Kathy Petoumenos; Christoph Boesecke; Chris Duncombe; Waldo H Belloso; Jean-Michel Molina; Lin Li; Anchalee Avihingsanon; Brian Gazzard; David A Cooper; Sean Emery
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;51(7):855-64.
2010: Dianne Carey; Janaki Amin; Mark Boyd; Kathy Petoumenos; Sean Emery
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
The Journal of antimicrobial chemotherapy 2010;65(9):1878-88.
2010: Amit C Achhra; Janaki Amin; Matthew G Law; Sean Emery; Jan Gerstoft; Fred M Gordin; Michael J Vjecha; James D Neaton; David A Cooper
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.
AIDS (London, England) 2010;24(12):1877-86.
2010: Sarah L Pett; Anthony D Kelleher; Sean Emery
Role of interleukin-2 in patients with HIV infection.
Drugs 2010;70(9):1115-30.
2010: Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah Puls; Kathy Petoumenos; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(6):920-9.
2009: Allison Martin; Mark Bloch; Janaki Amin; David Baker; David A Cooper; Sean Emery; Andrew Carr
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(10):1591-601.
2009: Helen Byakwaga; Christoph Boesecke; Sean Emery
Inflammation and gut permeability.
Journal of HIV therapy 2009;14(3):57-60.
2009: Sean Emery; Alan Winston
Raltegravir: a new choice in HIV and new chances for research.
Lancet 2009;374(9692):764-6.
2009: John J Zaunders; Mee Ling Munier; Nabila Seddiki; Sarah Pett; Susanna Ip; Michelle Bailey; Yin Xu; Kai Brown; Wayne B Dyer; Min Kim; Robert De Rose; Stephen J Kent; Lele Jiang; Samuel N Breit; Sean Emery; Anthony L Cunningham; David A Cooper; Anthony D Kelleher
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
Journal of immunology (Baltimore, Md. : 1950) 2009;183(4):2827-36.
2009: Mark Boyd; Sean Emery; David A Cooper
Antiretroviral roll-out: the problem of second-line therapy.
Lancet 2009;374(9685):185-6.
2009: Allison Martin; Sean Emery
Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy.
Expert review of clinical pharmacology 2009;2(4):381-90.
2009: Helen Byakwaga; John M Murray; Kathy Petoumenos; Anthony D Kelleher; Matthew G Law; Mark A Boyd; Sean Emery; Patrick W Mallon; David A Cooper
Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
AIDS research and human retroviruses 2009;25(6):756-76.
2009: D Carey; D Baker; Kathy Petoumenos; John Chuah; G D Rogers; J Watson; David A Cooper; Sean Emery; Andrew Carr
Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
HIV medicine 2009;10(3):163-72.
2009: H Byakwaga; Jialun Zhou; Kathy Petoumenos; Matthew G Law; Mark A Boyd; Sean Emery; David A Cooper; Patrick W G Mallon
Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.
HIV medicine 2009;10(3):143-51.
2009: Sarah L Pett; Michael C McCarthy; David A Cooper; Karen MacRae; Amol Tendolkar; Richard Norris; Julie M Strizki; Kenneth M Williams; Sean Emery
A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
Antiviral therapy 2009;14(1):111-5.
2008: Patrick W G Mallon; Rebecca Sedwell; Gary Rogers; David Nolan; Patrick Unemori; Jennifer Hoy; Katherine Samaras; Anthony D Kelleher; Sean Emery; David A Cooper; Andrew Carr
Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.
The Journal of infectious diseases 2008;198(12):1794-803.
2008: Sean Emery; Jacqueline A Neuhaus; Andrew N Phillips; Abdel Babiker; Calvin J Cohen; Jose M Gatell; Pierre-Marie Girard; Birgit Grund; Matthew Law; Marcelo H Losso; Adrian Palfreeman; Robin Wood
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
The Journal of infectious diseases 2008;197(8):1133-44.
2008: Dianne Carey; Steven Liew; Sean Emery
Restorative interventions for HIV facial lipoatrophy.
AIDS reviews 2008;10(2):116-24.
2007: Dianne L Carey; David Baker; Gary D Rogers; Kathy Petoumenos; John Chuah; Nicole Easey; Kirsty Machon; David A Cooper; Sean Emery; Andrew Carr
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):581-9.
2007: Handan Wand; Alexandra Calmy; Dianne L Carey; Katherine Samaras; Andrew Carr; Matthew G Law; David A Cooper; Sean Emery
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
AIDS (London, England) 2007;21(18):2445-53.
2007: John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
AIDS (London, England) 2007;21(17):2315-21.
2007: Sean Emery; Anthony D Kelleher; Cassy Workman; Rebekah L Puls; M Bloch; D Baker; J Anderson; Jennifer Hoy; S Ip; K Nalliah; L D Ward; Matthew G Law; David A Cooper
Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.
Human vaccines 2007;3(6):260-7.
2007: Alan Winston; Patrick W G Mallon; Claudette Satchell; Karen MacRae; Kenneth M Williams; Malte Schutz; Matthew Law; David A Cooper; Sean Emery
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1475-83.
2007: Katherine Samaras; Handan Wand; Matthew Law; Sean Emery; David Cooper; Andrew Carr
Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Diabetes care 2007;30(1):113-9.
2007: Wayne B Dyer; Sarah L Pett; John Sullivan; Sean Emery; David A Cooper; Anthony D Kelleher; Andrew Lloyd; Sharon R Lewin
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples.
Clinical and vaccine immunology : CVI 2007;14(1):52-9.
2006: Wafaa M El-Sadr; Jens D Lundgren; James D Neaton; Fred M Gordin; D Abrams; Roberto C Arduino; A Babiker; William Burman; Nathan Clumeck; C J Cohen; D Cohn; D Cooper; Janet Darbyshire; Sean Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; Marcelo H Losso; Norman Markowitz; J Neuhaus; A Phillips; C Rappoport
CD4+ count-guided interruption of antiretroviral treatment.
The New England journal of medicine 2006;355(22):2283-96.
2006: Mary Marrod; Sean Emery; Dominic E Dwyer
Antivirals in the management of an influenza pandemic.
The Medical journal of Australia 2006;185(10 Suppl):S58-61.
2006: Robert De Rose; Mark T Sullivan; C Jane Dale; Anthony D Kelleher; Sean Emery; David A Cooper; Ian A Ramshaw; David B Boyle; Stephen J Kent
Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials.
Human vaccines 2006;2(3):134-6.
2006: Mike Youle; Sean Emery; Martin Fisher; Mark Nelson; Lisa Fosdick; George Janossy; Clive Loveday; Ann Sullivan; Christian Herzmann; Handan Wand; Richard Davey; Margaret A Johnson; Jorge A Tavel; H Clifford Lane
A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study.
PLoS clinical trials 2006;1(1):e3.
2006: Alan Winston; Janaki Amin; Gillian Hales; David A Cooper; Sean Emery
Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals.
AIDS research and human retroviruses 2006;22(4):338-41.
2006: Alan Winston; Janaki Amin; Patrick W G Mallon; Debbie Marriott; Andrew Carr; David A Cooper; Sean Emery
Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
HIV medicine 2006;7(2):105-11.
2006: Anthony D Kelleher; Rebekah L Puls; Mark Bebbington; David Boyle; Rosemary Ffrench; Stephen J Kent; Susan Kippax; Damian F J Purcell; Scott Thomson; Handan Wand; David A Cooper; Sean Emery
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
AIDS (London, England) 2006;20(2):294-7.
2006: Gillian Hales; Chris Birch; Suzanne Crowe; Cassy Workman; Jennifer Hoy; Matthew G Law; Anthony D Kelleher; Douglas Lincoln; Sean Emery
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.
PLoS clinical trials 2006;1(3):e18.
2006: Rebekah L Puls; Sean Emery
Therapeutic vaccination against HIV: current progress and future possibilities.
Clinical science (London, England : 1979) 2006;110(1):59-71.
2005: Sean Emery; Cassy Workman; Rebekah L Puls; M Bloch; D Baker; NJ Bodsworth; J Anderson; Suzanne M Crowe; Martyn A French; Jennifer Hoy; A Aichelburg; L D Ward; David B Boyle; Matthew G Law; Anthony D Kelleher; David A Cooper
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
Human vaccines 2005;1(6):232-8.
2005: Alan Winston; Gillian Hales; Janaki Amin; Erno van Schaick; David A Cooper; Sean Emery
The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.
AIDS (London, England) 2005;19(13):1393-9.
2005: Dianne Carey; Handan Wand; Allison Martin; Sharyn Rothwell; Sean Emery; David A Cooper; Andrew Carr
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.
AIDS (London, England) 2005;19(12):1325-7.
2005: Alan Winston; Mark Bloch; Andrew Carr; Janaki Amin; Patrick W G Mallon; John Ray; Debbie Marriott; David A Cooper; Sean Emery
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
The Journal of antimicrobial chemotherapy 2005;56(2):380-7.
2005: Patrick W G Mallon; Patrick Unemori; Rebecca Sedwell; Adrienne Morey; Martina Rafferty; Kenneth Williams; Donald Chisholm; Katherine Samaras; Sean Emery; Anthony D Kelleher; David A Cooper; Andrew Carr
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.
The Journal of infectious diseases 2005;191(10):1686-96.
2005: Chris Duncombe; Stephen J Kerr; Kiat Ruxrungtham; Gregory J Dore; Matthew G Law; Sean Emery; Joep M A Lange; Praphan Phanuphak; David A Cooper
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.
AIDS (London, England) 2005;19(2):169-78.
2005: Jason C Kovacic; Allison Martin; Dianne Carey; Handan Wand; Patrick W G Mallon; Michael P Feneley; Sean Emery; David A Cooper; Andrew Carr
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Antiviral therapy 2005;10(1):135-43.
2004: C Jane Dale; Robert De Rose; Kim M Wilson; Hayley A Croom; Scott Thomson; Barbara E H Coupar; Alistair Ramsay; Damian F J Purcell; Rosemary Ffrench; Matthew Law; Sean Emery; David A Cooper; Ian A Ramshaw; David B Boyle; Stephen J Kent
Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12.
Vaccine 2004;23(2):188-97.
2004: Roberto C Arduino; Esteban C Nannini; Maria C Rodriguez-Barradas; Shannon Schrader; Marcelo H Losso; Kiat Ruxrungtham; Maria C Allende; Sean Emery; Lisa Fosdick; James D Neaton; Jorge A Tavel; Richard Davey; H Clifford Lane
CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(1):115-22.
2004: Chaiwat Ungsedhapand; Preeyaporn Srasuebkul; Peter Cardiello; Kiat Ruxrungtham; Winai Ratanasuwan; Eugene D M B Kroon; Metta Tongtalung; Nittaya Juengprasert; Sasiwimol Ubolyam; Umaporn Siangphoe; Sean Emery; Joep M A Lange; David A Cooper; Praphan Phanuphak
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):693-701.
2004: Allison Martin; Don E Smith; Andrew Carr; Clare Ringland; Janaki Amin; Sean Emery; Jennifer Hoy; Cassy Workman; Nicholas Doong; Judith Freund; David A Cooper
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
AIDS (London, England) 2004;18(7):1029-36.
2004: Sarah L Pett; Lisa A Williams; Richard O Day; Andrew R Lloyd; Andrew D Carr; Kathleen R Clezy; Sean Emery; Errol Kaplan; Dale A McPhee; Andrew J McLachlan; Frank B Gelder; Sharon R Lewin; Winston S Liauw; Kenneth M Williams
A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals.
HIV clinical trials 2004;5(2):91-8.
2004: Andrew Carr; Cassy Workman; Dianne Carey; Gary Rogers; Allison Martin; David Baker; Handan Wand; Matthew Law; Katherine Samaras; Sean Emery; David A Cooper
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
Lancet 2004;363(9407):429-38.
2003: Sunee Sirivichayakul; Kiat Ruxrungtham; Chaiwat Ungsedhapand; Wichai Techasathit; Sasiwimol Ubolyam; Theshinee Chuenyam; Sean Emery; David Cooper; Joep Lange; Praphan Phanuphak
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
AIDS (London, England) 2003;17(13):1889-96.
2003: J Amin; A Moore; Andrew Carr; M A French; Matthew Law; Sean Emery; David A Cooper
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
HIV clinical trials 2003;4(4):252-61.
2003: John Miller; Andrew Carr; Sean Emery; Matthew Law; Simon Mallal; D Baker; Don Smith; John Kaldor; David A Cooper
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.
HIV medicine 2003;4(3):293-301.
2003: Matthew G Law; Sean Emery
Selective exclusion of treatment arms in multi-arm randomized clinical trials.
Statistics in medicine 2003;22(1):19-30.
2003: David C Sayer; S Land; L Gizzarelli; Martyn French; Gillian Hales; Sean Emery; Frank T Christiansen; Elizabeth M Dax
Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.
Journal of clinical microbiology 2003;41(1):227-36.
2003: Chris Birch; Tracey Middleton; Gillian Hales; David Cooper; Matthew Law; Suzanne Crowe; Jennifer Hoy; Sean Emery
Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testing.
Journal of acquired immune deficiency syndromes (1999) 2003;32(1):57-61.
2002: Martyn French; Janaki Amin; Norman Roth; Andrew Carr; Matthew Law; Sean Emery; Fraser Drummond; David Cooper
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
HIV clinical trials 2002;3(3):177-85.
2002: Sean Emery; Donald I Abrams; David A Cooper; Janet H Darbyshire; H Clifford Lane; Jens D Lundgren; James D Neaton
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.
Controlled clinical trials 2002;23(2):198-220.
2002: Sean Emery; David A Cooper
HIV medicine.
The Medical journal of Australia 2002;176(1):21.
2001: Sarah L Pett; Sean Emery
Immunomodulators as adjunctive therapy for HIV-1 infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2001;22(3):289-95.
2000: Kiat Ruxrungtham; Surapol Suwanagool; Jorge A Tavel; M Chuenyam; Eugene D M B Kroon; Sasiwimol Ubolyam; Supranee Buranapraditkun; Wichai Techasathit; Y Li; Sean Emery; Richard Davey; Lisa Fosdick; Chaiyos Kunanusont; H Clifford Lane; Praphan Phanuphak
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand.
AIDS (London, England) 2000;14(16):2509-13.
2000: John Miller; Andrew Carr; Don Smith; Sean Emery; Matthew G Law; Pat Grey; David A Cooper
Lipodystrophy following antiretroviral therapy of primary HIV infection.
AIDS (London, England) 2000;14(15):2406-7.
2000: Sean Emery; W B Capra; David A Cooper; Ronald T Mitsuyasu; Joseph A Kovacs; P Vig; M Smolskis; Louis D Saravolatz; H Clifford Lane; Gwendolyn Fyfe; P T Curtin
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.
The Journal of infectious diseases 2000;182(2):428-34.
2000: Andrew Carr; John Chuah; Jeff Hudson; Martyn French; Jennifer Hoy; Matthew Law; David C Sayer; Sean Emery; David A Cooper
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
AIDS (London, England) 2000;14(9):1171-80.
2000: Marcelo H Losso; Waldo H Belloso; Sean Emery; Jorge Benetucci; Pedro Cahn; M C Lasala; G Lopardo; Horacio Salomon; M Saracco; E Nelson; M G Law; Richard Davey; M C Allende; H Clifford Lane
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
The Journal of infectious diseases 2000;181(5):1614-21.
1998: Andrew Carr; Sean Emery; A Lloyd; Jennifer Hoy; R Garsia; Martyn French; G Stewart; G Fyfe; David A Cooper
Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.
The Journal of infectious diseases 1998;178(4):992-9.
1998: Anthony D Kelleher; M Roggensack; Sean Emery; Andrew Carr; M A French; David A Cooper
Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.
Clinical and experimental immunology 1998;113(1):85-91.
1997: Anthony D Kelleher; Sean Emery; Philip Cunningham; Chris Duncombe; Andrew Carr; H Golding; S Forde; J Hudson; M Roggensack; B D Forrest; David A Cooper
Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.
AIDS research and human retroviruses 1997;13(1):29-32.